Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
- Status
- COMPLETED
- Phase
- PHASE1
Phase l/II Study of Ruxolitinib for Acute Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
- Status
- COMPLETED
- Phase
- PHASE3
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
- Status
- COMPLETED
- Phase
- PHASE3
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
- Status
- TERMINATED
- Phase
- PHASE2
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
- Status
- COMPLETED
- Phase
- PHASE2
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2